{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:37:03Z","timestamp":1792640223469,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Increasing rates of antibiotic resistance in Gram-negative organisms due to the presence of extended-spectrum beta-lactamases (ESBL), hyperproduction of AmpC enzymes, carbapenemases and other mechanisms of resistance are identified in common hospital- and healthcare-associated pathogens including Enterobacteriaceae, <jats:italic>Pseudomonas aeruginosa<\/jats:italic> and <jats:italic>Acinetobacter baumannii<\/jats:italic>.<\/jats:p>\n                <jats:p>Cefiderocol is a novel siderophore cephalosporin antibiotic with a catechol moiety on the 3-position side chain. Cefiderocol has been shown to be potent in vitro against a broad range of Gram-negative organisms, including carbapenem-resistant Enterobacteriaceae (CRE) and multi-drug-resistant (MDR) <jats:italic>P. aeruginosa<\/jats:italic> and <jats:italic>A. baumannii<\/jats:italic>. Recent clinical data has shown cefiderocol to be effective in the setting of complicated urinary tract infections and nosocomial pneumonia, but it has not yet been studied as treatment of bloodstream infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study will use a multicentre, open-label non-inferiority trial design comparing cefiderocol and standard of care antibiotics. Eligible participants will be adult inpatients who are diagnosed with a bloodstream infection with a Gram-negative organism on the basis of a positive blood culture result where the acquisition meets the definition for healthcare-associated or hospital-acquired. It will compare cefiderocol with the current standard of care (SOC) antibiotic regimen according to the patient\u2019s treating clinician. Eligible participants will be randomised 1:1 to cefiderocol or SOC and receive 5\u201314\u2009days of antibiotic therapy. Trial recruitment will occur in at least 20 sites in ten countries (Australia, Malaysia, Singapore, Thailand, Turkey and Greece). The sample size has been derived from an estimated 14\u2009day, all-cause mortality rate of 10% in the control group, and a non-inferiority margin of 10% difference in the two groups. A minimum of 284 patients are required in total to achieve 80% power with a two-sided alpha level of 0.05. Data describing demographic information, risk factors, concomitant antibiotics, illness scores, microbiology, multidrug-resistant organism screening, discharge and mortality will be collected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>With increasing antimicrobial resistance, there is a need for the development of new antibiotics with broad activity against Gram-negative pathogens such as cefiderocol. By selecting a population at risk for multi-drug-resistant pathogens and commencing study treatment early in the clinical illness (within 48\u2009h of index blood culture) the trial hopes to provide guidance to clinicians of the efficacy of this novel agent.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The GAME CHANGER trial is registered under the US National Institute of Health <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> register, reference number <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03869437\">NCT03869437<\/jats:ext-link>. Registered on March 11, 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05870-w","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T09:02:52Z","timestamp":1638867772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Hugh","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick N. A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Chatfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Harris-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"issue":"11","key":"5870_CR1","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1097\/CCM.0000000000000516","volume":"42","author":"C Vazquez-Guillamet","year":"2014","unstructured":"Vazquez-Guillamet C, Scolari M, Zilberberg MD, Shorr AF, Micek ST, Kollef M. Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock. Crit Care Med. 2014;42(11):2342\u20139. https:\/\/doi.org\/10.1097\/CCM.0000000000000516.","journal-title":"Crit Care Med"},{"issue":"6","key":"5870_CR2","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","volume":"34","author":"A Kumar","year":"2006","unstructured":"Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589\u201396. https:\/\/doi.org\/10.1097\/01.CCM.0000217961.75225.E9.","journal-title":"Crit Care Med."},{"issue":"4","key":"5870_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1097\/CCM.0b013e3181cc4824","volume":"38","author":"DF Gaieski","year":"2010","unstructured":"Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38(4):1045\u201353. https:\/\/doi.org\/10.1097\/CCM.0b013e3181cc4824.","journal-title":"Crit Care Med."},{"issue":"5","key":"5870_CR4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/jac\/dkl367","volume":"58","author":"JA Mart\u00ednez","year":"2006","unstructured":"Mart\u00ednez JA, et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum b-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother. 2006;58(5):1082\u20135. https:\/\/doi.org\/10.1093\/jac\/dkl367.","journal-title":"J Antimicrob Chemother."},{"issue":"3","key":"5870_CR5","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/jac\/dkv402","volume":"71","author":"A Ito","year":"2016","unstructured":"Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother. 2016;71(3):670\u20137. https:\/\/doi.org\/10.1093\/jac\/dkv402.","journal-title":"J Antimicrob Chemother."},{"issue":"2","key":"5870_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1128\/AAC.01695-15","volume":"60","author":"N Kohira","year":"2016","unstructured":"Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother. 2016;60(2):729\u201334. https:\/\/doi.org\/10.1128\/AAC.01695-15.","journal-title":"Antimicrob Agents Chemother."},{"issue":"12","key":"5870_CR7","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18(12):1319\u201328. https:\/\/doi.org\/10.1016\/S1473-3099(18)30554-1.","journal-title":"Lancet Infect Dis."},{"issue":"2","key":"5870_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2020","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2020;21(2):213\u201325. https:\/\/doi.org\/10.1016\/S1473-3099(20)30731-3.","journal-title":"Lancet Infect Dis."},{"issue":"2","key":"5870_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226\u201340. https:\/\/doi.org\/10.1016\/S1473-3099(20)30796-9.","journal-title":"Lancet Infect Dis."},{"issue":"2","key":"5870_CR10","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1016\/j.ijid.2012.09.008","volume":"17","author":"WU Lo","year":"2013","unstructured":"To KK, Lo WU, Chan JF, Tse H, Cheng VC, Ho PL. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity. Int J Infect Dis. 2013;17(2):e120\u20134. https:\/\/doi.org\/10.1016\/j.ijid.2012.09.008.","journal-title":"Int J Infect Dis."},{"issue":"10","key":"5870_CR11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","volume":"320","author":"PNA Harris","year":"2018","unstructured":"Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320(10):984\u201394. https:\/\/doi.org\/10.1001\/jama.2018.12163.","journal-title":"JAMA."},{"issue":"7","key":"5870_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","volume":"69","author":"D Yahav","year":"2019","unstructured":"Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven Versus 14\u2009Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. Clin Infect Dis. 2019;69(7):1091\u20138. https:\/\/doi.org\/10.1093\/cid\/ciy1054.","journal-title":"Clin Infect Dis."},{"issue":"3","key":"5870_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/BF02771841","volume":"26","author":"A Gikas","year":"1998","unstructured":"Gikas A, Samonis G, Christidou A, Papadakis J, Kofteridis D, Tselentis Y, et al. Gram-negative bacteremia in non-neutropenic patients: a 3-year review. Infection. 1998;26(3):155\u20139. https:\/\/doi.org\/10.1007\/BF02771841.","journal-title":"Infection."},{"issue":"2","key":"5870_CR14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1128\/AAC.49.2.760-766.2005","volume":"49","author":"CI Kang","year":"2005","unstructured":"Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 2005;49(2):760\u20136. https:\/\/doi.org\/10.1128\/AAC.49.2.760-766.2005.","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"5870_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/cid\/ciw741","volume":"64","author":"PD Tamma","year":"2017","unstructured":"Tamma PD, Goodman KE, Harris AD, Tekle T, Roberts A, Taiwo A, et al. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis. 2017;64(3):257\u201364. https:\/\/doi.org\/10.1093\/cid\/ciw741.","journal-title":"Clin Infect Dis."},{"issue":"43","key":"5870_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012984","volume":"97","author":"T Kim","year":"2018","unstructured":"Kim T, Lee EJ, Park SY, Yu SN, Lee YM, Park KH, et al. Natural prognosis of carbapenem-resistant Acinetobacter baumannii bacteremia in patients who did not receive appropriate antibiotic treatment: a retrospective multicenter study in Korea. Medicine (Baltimore). 2018;97(43):e12984. https:\/\/doi.org\/10.1097\/MD.0000000000012984.","journal-title":"Medicine (Baltimore)."},{"issue":"3","key":"5870_CR17","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1128\/AAC.01020-07","volume":"52","author":"MJ Schwaber","year":"2008","unstructured":"Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52(3):1028\u201333. https:\/\/doi.org\/10.1128\/AAC.01020-07.","journal-title":"Antimicrob Agents Chemother."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05870-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05870-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05870-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T09:19:19Z","timestamp":1638868759000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05870-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5870"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05870-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"5 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was given by The Royal Brisbane and Women\u2019s Hospital HREC. International sites will seek local HREC\/IRB approval as per local procedures. This study will be conducted in accordance with the ICH-GCP Guidelines and the principles in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"DLP has received funding from AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline (GSK), Cubist, Venatorx and Accelerate; reports board membership from Entasis, Qpex, Merck, Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GSK, Cubist, Venatorx and Accelerate; reports grants\/grants pending from Shionogi and Merck; and has received payment for lectures including service on speaker\u2019s bureaus from Pfizer, outside the submitted work. PNAH has received research grants from MSD, Shionogi and Sandoz, as well as speaker\u2019s fees from Pfizer. All other authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"889"}}